Spellman David A 4
4 · Akebia Therapeutics, Inc. · Filed Jun 10, 2022
Insider Transaction Report
Form 4
Spellman David A
SVP, CFO and Treasurer
Transactions
- Award
Common Stock
2022-06-08+200,000→ 328,599 total - Award
Stock Option (Right to buy)
2022-06-08+200,000→ 200,000 totalExercise: $0.45From: 2023-05-12Exp: 2032-06-08→ Common Stock (200,000 underlying)
Footnotes (2)
- [F1]The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"). The RSUs will vest in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date.
- [F2]The option to purchase shares of the Issuer's common stock ("the Stock Option") was granted by the Issuer pursuant to the 2014 Plan. The Stock Option will vest and become exercisable in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date.